Ask HopeStage to help me review this study
This study may no longer be open, but we can help you understand it and find similar studies.
Study ID: EUCTR 2022-000574-26. We help you review the study, but cannot decide medical eligibility.
Not recruitingEUCTR 2022-000574-26
A randomized, double-blind, placebo-controlled, Phase 2b trial with an open-label extension to determine the safety and efficacy of GH001 in patients with treatment-resistant depression
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
DepressionDrug
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Check recruitment and locations
EU CTR and CTIS records checked by HopeStage on . Registry information can change. Always confirm availability with the research team.
This study transferred to CTIS. HopeStage uses that newer record for the displayed status. A country's status does not guarantee that an individual site accepts participants.
View the historical EU CTR record
Current CTIS country statuses
Historical EU CTR country statuses
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
Czechia · 3 sites
- A-Shine s.r.o. — A-Shine s.r.o.Plzen 3Country status: Not recruiting
- INEP medical s.r.o. — Institut neuropsychiatrické péčePragueCountry status: Not recruiting
- Clintrial s.r.o. — CLINTRIAL s.r.o.Prague 10Country status: Not recruiting
Germany · 2 sites
- Goethe University Frankfurt — Klinik für Psychiatrie, Psychosomatik und PsychotherapieFrankfurt Am MainCountry status: Not recruiting
- Universitaetsklinikum Muenster AöR — Klinik für Psychische GesundheitMuensterCountry status: Not recruiting
Ireland · 1 site
- Tallaght Adult Mental Health Service — Sheaf House, Tallaght Adult Mental Health ServicesDublin 24Country status: Not recruiting
Poland · 1 site
- Uniwersyteckie Centrum Kliniczne — Klinika Psychatrii DoroslychGdanskCountry status: Not recruiting
Spain · 3 sites
- Hospital De La Santa Creu I Sant Pau — -BarcelonaCountry status: Not recruiting
- Hospital Del Mar — -BarcelonaCountry status: Not recruiting
- Parc Sanitari Sant Joan De Deu — -Sant Boi De LlobregatCountry status: Not recruiting
Key information made simple
What the source confirms
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
What should you check before joining?
Check the official protocol for eligibility, treatment, visits and assessments. If recruitment is listed, confirm with the team that a specific centre is still accepting participants before taking any next step.
Your next step
Study sites are listed in the registry. Recruitment status can differ between sites. Ask the research team to confirm the location, any in-person visits, time commitment, costs or compensation, and participation criteria.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Not recruiting
- Enrollment listed in the registry
- 80
- Sponsor
- GH Research Ireland Limited
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Czechia, Germany, Ireland, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2022-000574-26
- Official title
- A randomized, double-blind, placebo-controlled, Phase 2b trial with an open-label extension to determine the safety and efficacy of GH001 in patients with treatment-resistant depression
- Official source
- Official registry link
Ask HopeStage to help me review this study
This study may no longer be open, but we can help you understand it and find similar studies.
Study ID: EUCTR 2022-000574-26. We help you review the study, but cannot decide medical eligibility.
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What does the official source confirm?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Is this study recruiting?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
How can I check the participation requirements?
Check the official protocol for the criteria, treatment and planned assessments. The research team must confirm visits, risks, open centres and your eligibility.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
Not recruitingEUCTR 2022-002757-26
A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) i...
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Not recruitingEUCTR 2009-016648-38
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With ...
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Not recruitingEUCTR 2020-003720-16
A double-blind, placebo-controlled, randomized dose-ranging trial to investigate efficacy and safety of intravenous MIJ821 infusion in addition to comprehensive standard of care on the rapid reduct...
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.